Search Results - "BAJORIN, D"

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up by Fradet, Y., Bellmunt, J., Vaughn, D.J., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Nam, K., Frenkl, T.L., Perini, R.F., de Wit, R., Bajorin, D.F.

“…Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a…”
Get full text

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102 by Philips, G. K., Halabi, S., Sanford, B. L., Bajorin, D., Small, E. J.

“…Background: This phase II trial (Cancer and Leukemia Group B 90102) sought to determine the efficacy of cisplatin, standard infusion of gemcitabine and…”
Get full text

Detection of circulating tumor cells in patients with urothelial cancer by Gallagher, D. J., Milowsky, M. I., Ishill, N., Trout, A., Boyle, M. G., Riches, J., Fleisher, M., Bajorin, D. F.

“…Background: Approximately 50% of patients with metastatic urothelial cancer (UC) respond to chemotherapy and several months of therapy is required to assess…”
Get full text

BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC) by Rosenberg, J.E., Bajorin, D.F., Smith, A., D’Cruz, C., Lanasa, M.

Get full text

Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial by de Wit, R., Kulkarni, G.S., Uchio, E., Singer, E.A., Krieger, L., Grivas, P., Bajorin, D., Seo, H.K., Mourey, L., Kamat, A., Nishiyama, H., Kapadia, E., Nam, K., Frenkl, T., Balar, A.

Get full text

Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy by BAJORIN, D. F, DODD, P. M, MAZUMDAR, M, FAZZARI, M, MCCAFFREY, J. A, SCHER, H. I, HERR, H, HIGGINS, G, BOYLE, M. G

“…The variation in reported survival of patients with metastatic transitional-cell carcinoma (TCC) treated with systemic chemotherapy may be a consequence of…”
Get full text

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma by McCaffrey, J A, Hilton, S, Mazumdar, M, Sadan, S, Kelly, W K, Scher, H I, Bajorin, D F

“…A phase II trial of docetaxel was conducted to assess its efficacy and toxicity in patients with advanced transitional-cell carcinoma (TCC) who had failed to…”
Get more information

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045 by Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D., Choueiri, T.K., Necchi, A., Gerritsen, W.R., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Jensen, E., Frenkl, T., Perini, R.F., Bajorin, D.

Get full text

Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study by Necchi, A, Bellmunt, J, De Wit, R, Vaughn, D, Fradet, Y, Lee, J.L, Fong, L, Vogelzang, N, Climent, M, Petrylak, D, Choueiri, T, Gerritsen, W, Gurney, H, Quinn, D, Culine, S, Sternberg, C, Mai, Y, Puhlmann, M, Perini, R, Bajorin, D

Get full text

Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host by Gallagher, D.J., Vijai, J., Hamilton, R.J., Ostrovnaya, I., Iyer, G., Garcia-Grossman, I.R., Kim, P.H., Przybylo, J.A., Alanee, S., Riches, J.C., Regazzi, A.M., Milowsky, M.I., Offit, K., Bajorin, D.F.

“…Variations in urothelial carcinoma (UC) response to platinum chemotherapy are common and frequently attributed to genetic and epigenetic variations of somatic…”
Get full text

Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy by MAZUMDAR, M, BAJORIN, D. F, BACIK, J, HIGGINS, G, MOTZER, R. J, BOSL, G. J

“…The prognostic significance of the rate of decline of the serum tumor marker alpha-fetoprotein (AFP) and human chorionic gonadotrophin (HCG) during the first…”
Get full text

Commentary on “DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.” by Teo, MY, Bambury, RM, Zabor, EC, Jordan, E, Al-Ahmadie, H, Boyd, ME, Bouvier, N, Mullane, SA, Cha, EK, Roper, N, Ostrovnaya, I, Hyman, DM, Bochner, BH, Arcila, ME, Solit, DB, Berger, MF, Bajorin, DF, Bellmunt, J, Iyer, G, Rosenberg, JE

“…Platinum-based chemotherapy remains the standard treatment for advanced urothelial carcinoma by inducing DNA damage. We hypothesize that somatic alterations in…”
Get full text

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207 by Rosenberg, J. E., Halabi, S., Sanford, B. L., Himelstein, A. L., Atkins, J. N., Hohl, R. J., Millard, F., Bajorin, D. F., Small, E. J.

“…Background: There is no standard second-line treatment for advanced urothelial carcinoma (UC). Response rates to second-line chemotherapy for advanced UC are…”
Get full text

Deleterious Alterations in DNA Damage Response Genes Are Associated With Improved Outcome in Muscle-Invasive Bladder Cancer Patients Treated With Radiation-Based Bladder Preservation by Desai, N.B, Iyer, G.I, Cha, E.K, Scott, S.N, Hreiki, J, Sfakianos, J, Bagrodia, A, Bochner, B.H, Rosenberg, J.E, Bajorin, D, Berger, M.F, Kollmeier, M.A, Al-Ahmadie, H.A, Solit, D.B

Get full text

Association Between Geographic Access and Receipt of Radiation Therapy by Lin, C.C, Bruinooge, S, Kirkwood, K, Hershman, D.L, Jemal, A, Yu, J.B, Guadagnolo, B.A, Hopkins, S, Goldstein, M, Bajorin, D, Giordano, S, Kosty, M, Arnone, A, Hanley, A, Stevens, S, Olsen, C.C

Get full text

2650 Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma by Jordan, E, Won, H, Toubaji, A, Bagrodia, A, Desai, N, Bajorin, D, Rosenberg, J, Bochner, B, Kim, W, Berger, M, Solit, D, Al-Ahmadie, H, Iyer, G

Get full text

Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors by Galsky, M.D., Camacho, L.H., Chiorean, E.G., Mulkerin, D., Hong, D.S., Oh, W.K., Bajorin, D.F.

“…Satraplatin is an oral platinum analog with demonstrated activity in a range of malignancies. The current study was designed to evaluate the effect of varying…”
Get full text

Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment by Maluf, FC, Cordon-Cardo, C, Verbel, DA, Satagopan, JM, Boyle, MG, Herr, H, Bajorin, DF

“…Background: Tumor proliferation and apoptosis may be influenced by the mdm-2 gene product, which can block the antiproliferative effects of p53. bcl-2, one of…”
Get full text

Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome by Herr, H W, Bajorin, D F, Scher, H I

“…To evaluate the 10-year outcome of patients with invasive (T2-3N0M0, staged according to the tumor, node, metastasis system) bladder cancer who responded…”
Get more information

Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update by Gupta, Amit, Feifer, Andrew H, Gotto, Geoffrey T, Kraus, Dennis, Motzer, Robert, Bosl, George J, Bajorin, D, Feldman, Darren R, Carver, Brett, Sheinfeld, Joel

“…Objective To examine histologic findings and clinical outcomes of patients whounderwent neck dissection for residual neck masses. Methods From 1987 to 2008,…”
Get full text